Infasurf

This page contains recent news articles, when available, and an overview of Infasurf but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Forest Laboratories Inc. F2Q10 (Qtr End 30/09/09) Earnings Call Transcript  -  ‎Oct 20, 2009‎
...$14.9 million; Esgic, $0.6 million; Europe, $18.1 million; Generic, $6.5 million; Infasurf, $3.0 million; Lorcet, $1.5 million; Monurol, $0.4 million; ... Seeking Alpha (blog)

광�?�제약, '�?�파서프 주' 발매  -  ‎Nov 12, 2009‎
...광�?�제약(대표: 최수부)�?� 최근 미국 오니(Ony)사가 개발한 신�?아 RDS 치료제 '�?�파서프(Infasurf)주'를 �?�입, 출시했다고 29�?� �?혔다. 광�?�제약�? 따르면, ... 메디포뉴스

Recordati signs exclusive licence to sell Ony's Infasurf neonatal drug  -  Jun 23, 2006
MILAN (AFX) - Recordati SpA said it has signed an exclusive licence with US biotech company Ony Inc to sell in Europe Ony's Infasurf treatment for ... Forbes

… enters into agreement with Forest Laboratories to co-promote Infasu...  -  Feb 2, 2005
Infasurf is indicated for the prevention of Respiratory Distress Syndrome (RDS) in ... Infasurf decreases the incidence of RDS, mortality due to RDS, ... Free with registration - Asia Africa Intelligence Wire - AccessMyLibrary.com

… Update; INO Therapeutics, Forest Laboratories to co-promote Infasur...  -  Mar 1, 2005
Infasurf is indicated for the prevention of respiratory distress syndrome (RDS) in ... Infasurf decreases the incidence of RDS, mortality due to RDS, ... Pay-Per-View - Science Letter - Factiva, from Dow Jones

… Update; INO Therapeutics, Forest Laboratories to co-promote Infasur...  -  Mar 5, 2005
Infasurf is indicated for the prevention of respiratory distress syndrome (RDS) in ... Infasurf decreases the incidence of RDS, mortality due to RDS, ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones

한�?�약품, 美서 급성호�?�곤란�? 치료제 �?�입  -  Jan 7, 2008
...칼팩턴트'는 송아지�??�?서 추출한 천연 계면활성제로 미국 내�?서 시�?�?�고 있는 신�?아 호�?�곤란�?치료제 '�?�타서프'(Infasurf)와 �?��?�한 성분�?�다. ... 머니투�?��?�

Licensing deal opens doors in Europe for Amherst drug firm.  -  Jul 10, 2006
Infasurf, a lung surfactant derived from calf lungs, is used to prevent and treat ... So Infasurf, which is administered directly into the airspaces of the ... Free with registration - Buffalo News - AccessMyLibrary.com

Licensing deal opens doors in Europe for Amherst drug firm  -  Jul 8, 2006
Infasurf, a lung surfactant derived from calf lungs, is used to prevent and treat ... So Infasurf, which is administered directly into the airspaces of the ... $2.95 - Buffalo News - NewsBank

False-positive results on colorimetric carbon dioxide analysis in...  -  Jun 1, 2007
For both CCDDs tested, epinephrine, atropine, infasurf and naloxone created false-positive responses in the droplet exposure experiments. ... Nature.com

Con l'accordo con Ony Recordati riconferma la sua solidità  -  Jun 23, 2006
Infasurf è gia infatti presente sui mercati statunitense e israeliano dove è ... Infasurf, insieme allo Stannsoporfin, farmaco per l'ittero ottenuto in ... Milano Finanza

Building a future based on knowledge - Universities and the research ...  -  Sep 4, 2005
About 20000 infants a year receive Infasurf treatment, and the company is testing its effectiveness in older children. "We may be on the cusp of very rapid ... $2.95 - Buffalo News - NewsBank

Preterm Infants with Respiratory Distress Syndrome: Incidence Rates...  -  May 7, 2007
Infasurf is a registered trademark of Forest Pharmaceuticals, Inc. Media contacts: Dey, LP Media Line 1-800-755-5560 ext. 8363 or Harriet Ullman Feinstein ... Free with registration - PR Newswire - AccessMyLibrary.com

Press Release: Follow up on Samaritan Pharmaceuticals: License …  -  Jan 23, 2007
They have recently announced the signing of an exclusive license for the marketing and sales of U.S. approved Infasurf (calfactant), a specialist medication ... Pay-Per-View - M2 Presswire - HighBeam Research

OTHER NEWS TO NOTE.  -  Feb 3, 2005
Infasurf is indicated for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS and the treatment of premature ... Pay-Per-View - BIOWORLD Today - Factiva, from Dow Jones

Tutti i numeri di Recordati (2)  -  Mar 6, 2007
Infasurf®, insieme a Stanate® (stannsoporfin), farmaco ottenuto in licenza europea da Infacare Inc., USA, sarà la base per la presenza europea di Recordati ... SoldiOnline.it

Bloomberg Printer-Friendly Page  -  Jul 28, 2008
Elaprase and Replagal from Shire Pharmaceuticals, Infasurf from Ony, Inc, Erwinase, Kidrolase, and the Rapydan pain patch from EUSA, Mepivamol, ... Bloomberg

Acute airway obstruction by a sheared endotracheal intubation stylet ...  -  Apr 2, 2007
Exogenous surfactant (Infasurf), 3.4 ml in two aliquots, was administered via ETT within the first hour of life for persistently poor respiratory effort and ... Nature.com

Using siRNA in prophylactic and therapeutic regimens against SARS …  -  Aug 21, 2005
RLU) in mouse lungs after co-delivery of the expression plasmid pCI-scLuc and either siSC2-5 or siCONc-d, in either D5W or Infasurf solution. ... Nature.com

RECORDATI: 2007 ACCOUNTS APPROVED BY THE BOARD. …  -  Mar 5, 2008
The development of Stanate® and Infasurf®, two new neonatology products obtained under license, will surely benefit from the expertise which Orphan Europe ... marketwire.com

Samaritan Pharma Receives Pricing Approval in Greece for Rapydan(R) …  -  Jun 17, 2008
Elaprase and Replagal from Shire Pharmaceuticals, Infasurf from Ony, Inc, Erwinase, Kidrolase, and the Rapydan pain patch from EUSA, Mepivamol, ... Genetic Engineering News - Genetic Engineering News (press release)

RECORDATI buys Jaba's pharmaceutical business in Portugal  -  Jul 28, 2006
...for the treatment of neonatal hyperbilirubinemia), Infasurf(R) (for the prevention and treatment of neonatal Respiratory Distress Syndrome) and others". ... Genetic Engineering News - Genetic Engineering News (press release)

Samaritan's HIV Drug Granted IND From FDA  -  Jul 8, 2008
Elaprase and Replagal from Shire Pharmaceuticals, Infasurf from Ony, Inc, Erwinase, Kidrolase, and the Rapydan pain patch from EUSA, Mepivamol, ... RedOrbit

RECORDATI ACQUIRES ORPHAN EUROPE, A EUROPEAN GROUP …  -  Oct 1, 2007
...a number of extra-European countries and Infasurf® for Europe) and the development of these products will surely benefit from the expertise which Orphan ... marketwire.com

Discovery Labs Announces Topline Results of Surfaxin Phase 2 Clinical...  -  Oct 1, 2006
All the enrolled infants were obviously on mechanical ventilation and most have received, as I said, one of the currently approved either Survanta, Infasurf ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com

Lung Treatments For Premature Babies Under Study  -  May 8, 2007
...and 7277 got calfactant, marketed as Infasurf®. Results are being presented May 7 during the Pediatric Academic Societies Annual Meeting in Toronto. ... sciencedaily.com

A pink and blue symbolic gesture  -  Nov 4, 2005
...who will speak about Infasurf, the live-saving drug they created that reduces the morbidity and mortality of premature newborn infants. ... Buffalo Business First

Preterm Infants With RDS -- Surfactant Replacement Therapies Improves...  -  May 12, 2007
...therapies over which Curosurf® Intratracheal Suspension showed a nearly 20% mortality advantage are Survanta® (beractant) and Infasurf® (calfactant). ... Medical News Today - Medical News Today (press release)

Forest Laboratories Inc.  -  Jun 19, 2006
...uct; Infasurf, a treatment for respiratory conditions in premature infants; and Cervidil, used to aid in cervi-. cal dil. $35.00 - Stock Reports - Standard & Poor's

Lung Treatments For Premature Babies Assessed By Study  -  May 12, 2007
Premier Inc. 4953 got poractant alfa, marketed as Curosurf®; 12653 got beractant marketed as Survanta®; and 7277 got calfactant, marketed as Infasurf®. ... Medical News Today - Medical News Today (press release)

�?�료계 정론 메디�?�뉴스  -  Jan 5, 2008
...칼팩턴트는 송아지 �??�?서 추출한 천연 계면활성제로서, FDA�?� 승�?��?� 거�? 현재 미국 �?서 시�?�?�고 있는 신�?아호�?�곤란�? 치료제 Infasurf과 �?��?�한 성분�?� 물질 ... 메디�?�뉴스

Lung Research; Technique allows lung-specific delivery of reagents  -  Jan 25, 2005
..."As proof of principle, we took advantage of the spreading ability of pulmonary surface active material (InfaSurf), mixed it with elastase, ... Pay-Per-View - Science Letter - Factiva, from Dow Jones

Children's Hospital of Philadelphia, Philadelphia,; Research by...  -  Dec 19, 2006
...six GC-treated and five non-GC lambs were administered surfactant (Infasurf, 3 mg/kg) at birth. Six sham-operated lambs served as controls. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones

Discovery Labs Submits Response to Second FDA Approvable Letter  -  Nov 28, 2007
If approved, Surfaxin would compete against Abbott Laboratories' Survanta (beractant), Forest Pharmaceuticals' Infasurf (calfactant) and Mylan subsidiary ... FDA news - FDA news (subscription)

Lung Research; Technique allows lung-specific delivery of reagents  -  Jan 29, 2005
..."As proof of principle, we took advantage of the spreading ability of pulmonary surface active material (InfaSurf), mixed it with elastase, ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones

Developmental Biology; Diaphragmatic hernia-associated abnormal …  -  Sep 26, 2006
...six GC-treated and five non-GC lambs were administered surfactant (Infasurf, 3 mg/kg) at birth. Six sham-operated lambs served as controls. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones

Study assesses lung treatments for premature babies  -  Sep 5, 2007
Premier Inc. 4953 got poractant alfa, marketed as Curosurf®; 12653 got beractant marketed as Survanta®; and 7277 got calfactant, marketed as Infasurf®. ... innovations report

Factiva Search  -  Mar 4, 2005
Business Update; INO Therapeutics, Forest Laboratories to co-promote Infasurf. 04 March, 2005 Drug Week. 2005 MAR 4 - (NewsRx.com & NewsRx.net) -- INO ... Pay-Per-View - Drug Week - Factiva, from Dow Jones

Event Brief of Q1 2008 Forest Laboratories, Inc. Earnings Conference...  -  Jul 17, 2007
Infasurf, $3.2m. 10. Lorcet, $2.6m. 11. Monurol, $300000. 12. Tessalon, $4.6m. 13. Thyroid products, $15.4m. 14. Tiazac branded, $3.4m. 15. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com

Factiva Search  -  Feb 28, 2005
Business Update; INO Therapeutics, Forest Laboratories to co-promote Infasurf. 28 February, 2005 Health & Medicine Week ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones

+0,34% l'S&P/Mib grazie ai titoli oil, lo shopping in Cina fa bene a ...  -  Jun 23, 2006
...che ha siglato un contratto di licenza esclusiva con la società biotecnologica statunitense Ony Inc. per la commercializzazione in Europa di Infasurf, ... Milano Finanza

Factiva Search  -  Feb 28, 2005
Business Update; INO Therapeutics, Forest Laboratories to co-promote Infasurf. 28 February, 2005 Pharma Business Week ... Pay-Per-View - Pharma Business Week - Factiva, from Dow Jones

Abbott Laboratories, Columbus, OH, July 15 (DDMAC).(DDMAC PROMO …  -  Aug 1, 2005
...compared to 11 of 30 Infasurf-treated infants (P=0.007)"; and, "although Survanta infants weighed significantly less at entry, survival was ... $4.95 - Warning Letter Bulletin - ECNext

Press Release: Forest Laboratories Announces Termination of …  -  Feb 6, 2007
Infasurf(R). The FDA found that the new information ... of the new data, the FDA indicated that it will ... President - Finance, of Forest Laboratories, ... Pay-Per-View - PR Newswire - HighBeam Research

Carbon.(HEALTH-CARE AD AGENCIES 2005)  -  Apr 1, 2005
For Ino Therapeutics (inotherapeutics.com), Carbon handles Inomax for hypoxemic respiratory failure and Infasurf for neonatal respiratory distress syndrome. ... Pay-Per-View - Med Ad News - Factiva, from Dow Jones

Orphan Europe valutata a multipli elevati, ma è una mossa strategica...  -  Oct 1, 2007
...l'acquisizione di competenze che dovrebbero facilitare l'approvazione dei farmaci in licenza Stanate e Infasurf", sottolinea l'analista di una sim ... Milano Finanza

Seattle biotech Ikaria merging with New Jersey firm. | Article from...  -  Feb 22, 2007
INO Therapeutics Enters Into Agreement With Forest Laboratories to Co-Promote Infasurf(R) (Calfactant) Intratracheal Suspension. PR Newswire; February 2, ... Pay-Per-View - Seattle Times - HighBeam Research

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.